Noxopharm announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.
“Based on preclinical and clinical data, the FDA’s approval of this IND is validation of the clinical potential of Veyonda®,” said Noxopharm CMO Gisela Mautner, M.D., Ph.D. “Further, it means that Veyonda® has met stringent FDA standards for safety and tolerability.”
“While the Company’s resources and energies are primarily focused on bringing a treatment for late-stage prostate cancer to market, this IND grant for a less common cancer type advances that commercial objective,” said Noxopharm CEO Graham Kelly, Ph.D. “The recent IND approval process has familiarized the FDA with Veyonda® ahead of IND applications for more advanced DARRT and LuPIN study submissions. It also opens the door to Veyonda®’s use in the U.S., where patient demand has been growing.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Veyonda® is a suppository dosage form of idronoxil, a first-in-class inhibitor of sphingosine-1-phosphate (S1P). By inhibiting the overexpression of S1P-driven pro-survival pathways in solid tumors, idronoxil is designed to sensitize cancer cells to the anti-cancer effects of drugs such as doxorubicin, as well as to radiation.
Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada.